ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Insmed Incorporated (INSM) stock surged +1.91%, trading at $98.73 on NASDAQ, up from the previous close of $96.88. The stock opened at $96.46, fluctuating between $96.01 and $99.65 in the recent session.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Employees | 1271 |
Beta | 0.79 |
Sales or Revenue | $305.21M |
5Y Sales Change% | 15.981% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Pharmaceuticals |